The best of EcoWatch, right in your inbox. Sign up for our email newsletter!
CVS and Walgreens Stop Selling Zantac After Cancer-Causing Chemical Detected
By Julia Ries
Weeks after the popular heartburn drug ranitidine, known by the brand name Zantac, was found to contain a cancer-causing chemical, multiple drugstores have decided to no longer sell the medication.
CVS and Walgreens will no longer sell Zantac and other ranitidine medications, as the heartburn drugs might contain substances that could cause cancer.
Even though Zantac hasn't officially been recalled, CVS is currently offering customers who recently bought Zantac or another ranitidine drug a refund. The chain will continue to sell other over-the-counter heartburn medications, like Pepcid and Tagamet, which don't contain ranitidine.
Although Sanofi, the company that owns Zantac, hasn't issued a recall, the drug companies Apotex Corp. and Sandoz Inc. announced they're voluntarily recalling all of their ranitidine-based products sold in the U.S. due to the risk.
Potentially Harmful Chemical Detected
About two weeks ago, the FDA reported small amounts of a cancer-causing chemical called N-nitrosodimethylamine (NDMA) were detected in several brand-name and generic heartburn medications.
Even though the FDA identified the carcinogen, the organization isn't yet recommending people stop taking ranitidine products.
This affects the many people who regularly use ranitidine medications to prevent and treat heartburn, ulcers and gastroesophageal reflux disease (GERD).
The FDA is investigating whether the low levels found in the ranitidine medicines create a health risk.
Once the FDA has that information, it'll share it. But for now, the agency isn't recommending people stop taking ranitidine.
"Although NDMA may cause harm in large amounts, the levels the FDA is finding in ranitidine from preliminary tests barely exceed amounts you might expect to find in common foods," Dr. Janet Woodcock, the director of the FDA's Center for Drug Evaluation and Research, said in a statement.
You Don't Need to, but You Can Switch Drugs
Sanofi, the company that makes Zantac, is cooperating with the FDA to ensure the drug is safe for consumers.
"Sanofi takes patient safety seriously and we are committed to working with the FDA. Zantac OTC (over the counter) has been around for over a decade and meets all the specified safety requirements for use in the OTC market," a Sanofi spokesperson told Healthline in an earlier statement.
If you take a medication with ranitidine, you might want to consider opting for a different drug — though it's not necessary at this time.
Cimetidine, known as Tagamet, and famotidine, or Pepcid, are two other types of OTC medications commonly used to treat heartburn and acid reflux.
If you have a prescription, your doctor can recommend another treatment option.
"While Zantac may prove safe in the long run, this latest statement adds confusion and concern so my interim advice to patients is simple: switch to another drug (there are other options), and of course confirm with your doctor the need for an antacid," Dr. David Robbins, the associate chief of endoscopy at Lenox Hill Hospital, said in statement.
Dr. Linda Nguyen, a gastroenterologist at Stanford Health Care in California, has similar advice.
"According to the FDA alert, the issue does not appear to be related to the drug class but due to contaminants specific to ranitidine," Nguyen told Healthline.
"Ranitidine is an H2 (histamine-2) blocker that decreases the acidity in the stomach. It is frequently used for heartburn and dyspepsia (stomach upset or indigestion). Ranitidine is available over the counter and [by] prescription. There are alternative H2 blockers available in the U.S., including famotidine (Pepcid) or cimetidine (Tagamet). Patients should consult with their clinician or pharmacist for equivalent dose conversions," Nguyen said.
What Is NDMA?
NDMA is an environmental contaminant found in water along with meat, dairy and vegetables.
It's classified as a B2 carcinogen, meaning it's a probable human carcinogen. Exposure to high amounts of NDMA is thought to cause gastric or colorectal cancer, according to the World Health OrganizationTrusted Source.
It's extremely toxic to the liver. Even small amounts may be linked to liver damage.
The chemical was once used to make rocket fuel. Today, the chemical is only used for research purposes in the U.S., according to the Environmental Protection Agency.
The chlorination of drinking and wastewater, which treatment plants do to purify our water, can unintentionally create NDMA as well.
NDMA Was Found in Blood Pressure Drugs Earlier This Year
Since last year, the FDA has been investigating NDMA in certain blood pressure and heart failure medicines categorized as angiotensin II receptor blockers.
In July, the agency issued a handful of recalls of blood pressure medications after a concerning amount of NDMA was found in the drugs valsartan, losartan and irbesartan.
The FDA estimated that if 8,000 people took the highest dose of the recalled valsartan daily for four years, there'd be just one additional cancer case from that group of people.
The FDA stressed the importance of continuing to take the medications until a healthcare provider could recommend a replacement.
If you experience any side effects after taking these blood pressure medications or any heartburn medications with ranitidine, report it to the FDA's MedWatch Program.
The Bottom Line
CVS and Walgreens will no longer sell certain ranitidine heartburn medications, including Zantac.
The news comes after the FDA announced that ranitidine heartburn medications may contain traces of a cancer-causing chemical known as N-nitrosodimethylamine (NDMA).
The agency is currently looking into the health risks associated with the amount of NDMA identified in the drugs. It will post more information as it learns more.
As of now, the FDA isn't recommending people stop taking ranitidine, but those who'd like to switch medications should talk to their doctor about other treatment options.
Reposted with permission from our media associate Healthline.
EcoWatch Daily Newsletter
By Pedro Biondi
Extinct in its habitat for at least three decades, the Alagoas curassow (Pauxi mitu) is now back in the jungle and facing a test of survival, thanks to the joint efforts of more than a dozen institutions to pull this pheasant-like bird back from the brink.
By Julia Conley
Sen. Elizabeth Warren expanded her vision for combating the climate crisis on Tuesday with the release of her Blue New Deal — a new component of the Green New Deal focusing on protecting and restoring the world's oceans after decades of pollution and industry-caused warming.
A judge in New York's Supreme Court sided with Exxon in a case that accused the fossil fuel giant of lying to investors about the true cost of the climate crisis. The judge did not absolve Exxon from its contribution to the climate crisis, but insisted that New York State failed to prove that the company intentionally defrauded investors, as NPR reported.
By Sharon Elber
You may have heard that giving a pet for Christmas is just a bad idea. Although many people believe this myth, according to the ASPCA, 86 percent of adopted pets given as gifts stay in their new homes. These success rates are actually slightly higher than average adoption/rehoming rates. So, if done well, giving an adopted pet as a Christmas gift can work out.